DXCM

In the past six months, DexCom reported strong Q2 2026 results with revenue of $1.31 billion, up 13.1% year-over-year and exceeding consensus estimates, alongside an earnings per share beat of $0.70. Leadership changes occurred in September 2026, with Jereme Sylvain promoted to Chief Operating Officer in addition to his CFO duties, and Glenn Boehnlein appointed to the Board of Directors. Analyst sentiment has been largely positive, with firms like Truist Securities, TD Cowen, RBC, and Barclays upgrading ratings or raising price targets. DexCom released its 'State of Type 2 Report' at EASD 2026, highlighting growth opportunities for CGM in Type 2 diabetes management, and announced a partnership making it the official CGM provider for Team Novo Nordisk. The stock experienced a 52-week high of $92.59 on August 24, 2026, and a 52-week low of $54.11 on November 7, 2025, trading around $84-$86 in early October 2026. An auditor change from Ernst & Young LLP to Deloitte & Touche LLP was reported in February 2026.